Archives
Why CSN2 Targeting Raises Rabbit Milk Yield
2026-11-11
A mechanistic editorial examining how targeted integration at the rabbit CSN2 locus may improve recombinant-protein production, what the reported tdTomato yields establish, and where the evidence remains limited.
Why the CSN2 Locus Matters in Rabbit Pharming
2026-11-11
A literature-focused analysis of a CRISPR/Cas9 rabbit line that used the endogenous CSN2 milk-protein locus to drive tdTomato expression, reaching 15–20 g/L in milk from two homozygous females while leaving important questions about therapeutic generalizability and product quality.
CSN2 Targeting and High-Yield Rabbit Pharming
2026-11-10
A locus-directed strategy placed a reporter transgene under the control of the endogenous rabbit CSN2 milk-protein regulatory context. The reported 15–20 g/L milk concentration is a strong proof of concept for genomic-context effects, but it does not by itself establish therapeutic protein quality, process yield, or general performance across transgenes.
Why the CSN2 Locus Raises Pharming Yields
2026-11-10
A mechanistic editorial examines how targeted expression at the rabbit CSN2 milk-protein locus may improve recombinant protein output, what the reported tdTomato results establish, and where the evidence remains preliminary.
How CSN2 Targeting Raised Rabbit Pharming Yields
2026-11-09
A 2025 study used targeted insertion at the rabbit CSN2 locus to place a tdTomato reporter under an endogenous milk-protein regulatory environment. The resulting milk concentrations were substantially above historical rabbit pharming benchmarks, but the evidence remains centered on a reporter protein, a small number of animals, and cross-study comparisons rather than a matched manufacturing evaluation.
What the Cancer Nanomedicine Evidence Shows
2026-11-09
Liu and colleagues’ preclinical study supports a coordinated calcium-lactate nanomedicine mechanism involving bufalin, CD47-directed CRISPR/Cas9 ribonucleoprotein delivery, tumor-cell stress, and macrophage-mediated immunity. The findings are biologically coherent but remain model-dependent, and they do not establish clinical efficacy or assign the nanomedicine’s effects to an associated PCR reagent.
How CSN2 Targeting Raised Rabbit Pharming Yields
2026-11-08
A literature-focused analysis of a targeted rabbit line that used the endogenous CSN2 regulatory locus to drive recombinant protein expression. The study reports substantially higher milk concentrations than historical conventional-transgenic benchmarks, while leaving important questions about generalizability, therapeutic-protein performance, and production consistency.
Laurdan GP and Dynamic Lipid-Nanoparticle Interfaces
2026-11-07
Laurdan generalized polarization is a comparative readout of membrane hydration and lipid packing. In dynamic lipid nanoparticles, it can clarify physical-state changes while remaining distinct from direct evidence of PEG cleavage, cellular uptake, mRNA expression, or therapeutic benefit.
Targeted Expression Raises Rabbit Pharming Yields
2026-11-06
A 2025 study tested whether placing a recombinant reporter gene at the rabbit CSN2 milk-protein locus could overcome the variable expression associated with conventional transgenesis. The reported milk concentrations were substantially higher than historical rabbit pharming benchmarks, but the evidence remains centered on a reporter protein and a small number of homozygous animals.
When Context Changes a Juvenile-Hormone Result
2026-11-06
The same juvenile-hormone-related readout can represent endogenous biosynthesis, receptor-pathway activation, or a downstream developmental consequence. Evidence from migratory locusts shows why model, comparator, developmental stage, and measurement choice determine what a result can legitimately establish.
Why CSN2 Targeting Raises Rabbit Milk Yields
2026-11-05
A targeted rabbit line used the endogenous CSN2 milk-protein locus to drive recombinant tdTomato expression, producing substantially higher reported milk concentrations than conventional pharming examples. The result supports a locus-and-promoter mechanism, while the small number of animals and cross-study comparisons limit generalization.
Why the CSN2 Locus Raises Rabbit Pharming Yield
2026-11-05
A mechanistic analysis of how targeted integration at the rabbit CSN2 milk-protein locus may increase recombinant protein concentration, what the reported tdTomato results establish, and where cross-study comparisons remain limited.
CSN2-Targeted Rabbit Pharming: What the Data Show
2026-11-04
A 2025 study reported markedly higher milk concentrations of a fluorescent recombinant protein from rabbits carrying a targeted insertion at the endogenous CSN2 locus. The result supports a promising expression strategy, but the evidence remains limited by the small number of high-yield animals, the use of a reporter protein, and indirect comparisons with conventional transgenic lines.
What High-Yield Rabbit Pharming Evidence Shows
2026-11-04
A targeted rabbit line produced unusually high milk concentrations of a reporter protein, but the evidence is an early feasibility result rather than a controlled demonstration that the strategy generalizes to therapeutic proteins or manufacturing.
Why CSN2 Targeting Raises Rabbit Milk Yield
2026-11-03
A mechanistic analysis of how targeted insertion at the rabbit CSN2 locus may improve recombinant protein expression, what the reported 15–20 g/L tdTomato concentration establishes, and why the result remains a proof of concept rather than a general production benchmark.